A Randomized Trial of DOTS Versus Enhanced DOTS for Community Control of Tuberculosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Rio de Janeiro, Brazil, 21945
- Municipal Health Department
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Cases will include:
- Any age male or female with new or recurrent diagnosis of TB
- Willingness and ability to adhere to study medications and protocol procedures.
- Willingness to provide signed informed consent or signed informed consent/assent provided by parent or legal guardian.
Contacts will include:
- Male or female living in household of a pulmonary TB case, at high risk for developing TB (but without evidence for active TB).
High-risk household contacts will be defined as those who are:
- HIV seropositive, regardless of the results of initial tuberculin skin test (TST)
- TST positive at the time of the first household evaluation. TST positivity will be defined as greater than or equal to 5 mm induration of 5 TU of PPD using the Mantoux method, read between 48 and 72 hours after application.
- TST negative at the time for the first household evaluation and TST positive at the time of the second household evaluation 3 months later.
- Willingness to provide signed informed consent or signed informed consent/assent provided by parent or legal guardian.
Exclusion Criteria:
Contacts will be excluded from preventive therapy if:
- Current active clinical tuberculosis-confirmed or suspected
- History of sensitivity/intolerance to any of the study medications
- Evidence of acute hepatitis
- History or laboratory evidence of cirrhosis
- Pregnant females (treatment of latent infection will be deferred)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Actinomycetales Infections
- Mycobacterium Infections
- Tuberculosis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antimetabolites
- Hypolipidemic Agents
- Lipid Regulating Agents
- Anti-Bacterial Agents
- Leprostatic Agents
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- Antitubercular Agents
- Antibiotics, Antitubercular
- Cytochrome P-450 CYP2B6 Inducers
- Cytochrome P-450 CYP2C8 Inducers
- Cytochrome P-450 CYP2C19 Inducers
- Cytochrome P-450 CYP2C9 Inducers
- Fatty Acid Synthesis Inhibitors
- Rifampin
- Isoniazid
- Pyrazinamide
Other Study ID Numbers
Other Study ID Numbers
- 01-581
- ICIDR#1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.